0001013762-23-006961.txt : 20231026 0001013762-23-006961.hdr.sgml : 20231026 20231026163052 ACCESSION NUMBER: 0001013762-23-006961 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231026 FILED AS OF DATE: 20231026 DATE AS OF CHANGE: 20231026 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Enlivex Therapeutics Ltd. CENTRAL INDEX KEY: 0001596812 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36578 FILM NUMBER: 231350568 BUSINESS ADDRESS: STREET 1: 37 DEREH MENACHEM BEGIN ST. STREET 2: 15TH FLOOR CITY: TEL AVIV STATE: L3 ZIP: 6522042 BUSINESS PHONE: 972 (0) 3 7326616 MAIL ADDRESS: STREET 1: 37 DEREH MENACHEM BEGIN ST. STREET 2: 15TH FLOOR CITY: TEL AVIV STATE: L3 ZIP: 6522042 FORMER COMPANY: FORMER CONFORMED NAME: Bioblast Pharma Ltd. DATE OF NAME CHANGE: 20160919 FORMER COMPANY: FORMER CONFORMED NAME: BIO BLAST PHARMA LTD. DATE OF NAME CHANGE: 20140113 6-K 1 ea187335-6k_enlivex.htm REPORT OF FOREIGN PRIVATE ISSUER

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: October 2023

Commission file number: 001-36578

ENLIVEX THERAPEUTICS LTD.

(Translation of registrant’s name into English)

14 Einstein Street, Nes Ziona, Israel 7403618

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Annual General Meeting of Shareholders

On October 26, 2023, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), convened its 2023 Annual General Meeting of Shareholders of the Company (the “Annual Meeting”); however, the meeting was adjourned for one week, to the same time and place, due to lack of quorum. Accordingly, the Annual Meeting will be reconvened on Thursday, November 2, 2023, beginning at 7:00 p.m. Israel time, at the offices of the Company located at 14 Einstein Street, Ness Ziona, Israel 7403618. The voting deadline for receipt by the Company or the Company's transfer agent of a mailed proxy has been extended to October 30, 2023 by 7:00 p.m. Israel time and the deadline for the Company’s shareholders to vote by telephone or internet has been extended to October 29, 2023 by 11:59 p.m.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Enlivex Therapeutics Ltd.
	(Registrant)

	By:	/s/ Oren Hershkovitz
	Name: Title:	Oren Hershkovitz Chief Executive Officer

Date: October 26, 2023